Quick Links

Mechanism of action of novel HCV NS5A inhibitors

Project Information
Description: 

Approximately 200 million people worldwide are infected with the hepatitis C virus (HCV). The vast majority develop chronic infection that is associated with severe liver disease, including hepatic fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Thus, there is a need for the development of treatments that cure infected individuals. Compounds that bind to the non-structural protein 5A (NS5A) have shown antiviral activity in advances clinical trials. In collaboration with Tibotech, we study the mechanism of action of selected molecules with the ultimate goal to provide tools to improve this class drugs.

Project Date: 
2011-01-01 - 2022-09-29
Type of Project: 
Research
Research Area: 
Health Research
Sub-Research Area: 
Virology

Location

Belgium

McGill University Project Leader Information

Project Leader: 

Matthias Gotte

Primary Position

Faculty: 
Faculty of Medicine
Department: 
Microbiology & Immunology
Position/Appointment: 
Professor
Research Interests: 
Research in his group is focused on structure-function relationships of viral enzymes, with emphasis placed on mechanisms involved in drug action and drug resistance. The reverse transcriptase (RT) of HIV-1, the RNA-dependent RNA polymerase and helicase of the hepatitis C virus (HCV), and herpes virus DNA polymerases are major themes. The lab is actively involved in the development of novel classes of compounds that block the DNA polymerase activity of wild-type HIV-1 RT and its resistant variants.
Role: 
Principal Investigator

Non-McGill Partners

Partner: 

Frederik Pauwels

Country: 
Belgium
University/Organization: 
Tibotec (Johnson & Johnson)
Role: 
Collaborator